Credits Available: 4.5 AMA PRA Category 1 Credit™ & 4.5 MOC points, 4.5 ACPE

Description: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries, with an age-adjusted incidence of 4.6 per 100,000 individuals per year. As small lymphocytic lymphoma (SLL) refers to the same malignant process with primary nodal involvement rather than blood, these are generally managed as a single condition (CLL/SLL). The selection of therapies for patients with relapsed/refractory CLL/SLL requires consideration of several factors including previous therapies, disease characteristics, and patient-specific factors such as co-morbidities and concurrent medications. Given the recency of new research into these targeted treatments and new approvals, clinicians lack background knowledge of the most current evidence and guideline recommendations in the treatment of CLL/SLL. Even within national guidelines, specific recommendations for initial treatment choice and sequencing are not directed. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL).

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Hematology, Hematology/Oncology, Oncology

Izidore Lossos

University of Miami

Dr. Izidore Lossos is Professor of Medicine and the Director of Lymphoma Program and Chief of Lymphoma Section at Sylvester Comprehensive Cancer Center at University of Miami. He holds a Sylvester endowed chair at the NCI designated Sylvester Comprehensive Cancer Center. He received his medical degree from Hadassah School of Medicine, Hebrew University in Jerusalem, Israel. He completed his residency in Internal Medicine and fellowship in Hematology at Hadassah University Hospital in Jerusalem and postdoctoral fellowship with major emphasis on lymphoma at Division of Medical Oncology at Stanford University.
The focus of Dr. Lossos’s research is pathogenesis of lymphoma, identification of molecular prognostic markers and elucidation of their role in determination of response to therapy, development of new lymphoma therapies and advancing understanding and treatment of MZL. His studies focus on diffuse large cell lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, primary CNS lymphoma, lymphomas of the eye and other lymphoma subtypes. His research involves clinical studies of novel therapies and basic research at the bench and translation of these findings to clinical trials. He participated in multiple clinical trials as a PI or co-PI. He has authored multiple reviews, commentaries and book chapters as well as more than 320 peer-reviewed articles in such journals as New England Journal of Medicine, Blood, Proceedings of the National Academy of Sciences USA, Nature, Cell, Nature Communications, Cancer Cell, Cancer Discovery, EMBO, Journal of Clinical Investigations, Journal of Clinical Oncology, Leukemia, Journal of Immunology, Cancer and others.
He is a recipient of the 2007- Celgene Young Investigator Award for Achievements in Clinical Hematology and the 2012 and 2020 – Sylvester Comprehensive Cancer Center Outstanding Cancer Research Award and 2020 Schally Research Award in Internal Medicine. Since 2004 and till 2020 he is recognized as an America’ Top Doctor by the A Castle Connolly Guide and in 2011-2016 was recognized as Top Doctor by US News and World Report. He serves on an Advisory board of Lymphoma Foundation.